ReviewDiagnostics (Basel, Switzerland)2026
Historical Evolution of Terminology and Current Classification of Neuroendocrine Neoplasms of the Larynx and Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms (MiNENs): A Narrative Review.
Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
This is a narrative review that describes the evolution of terminology and classification schemes of neuroendocrine tumors (NETs), neuroendocrine carcinomas (NECs), mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs), and paragangliomas of the larynx, with the contribution of immunohistochemistry and treatment of neuroendocrine neoplasms of the larynx. Neuroendocrine neoplasms of the larynx comprise both epithelial (NET and NEC) and neural crest-derived (paraganglioma) neoplasms. Their terminology has evolved substantially over time, with current classifications emphasizing biologically and clinically meaningful categories aligned with contemporary WHO frameworks of other organs. These neoplasms may show overlapping clinical presentation and histomorphological features, which can complicate accurate subclassification. However, precise classification is essential, as these entities display markedly different biological behavior, ranging from indolent to highly aggressive with poor prognosis, and their treatment is essentially histology-tailored. Neuroendocrine neoplasms are classified into three categories comprising six tumor subtypes: well-differentiated neuroendocrine tumors (NETs; grades 1, 2, and 3), poorly differentiated neuroendocrine carcinomas (NECs; small-cell and large-cell types), and paragangliomas. An additional, not yet WHO-recognized category is MiNENs (mixed neuroendocrine-non-neuroendocrine neoplasms), defined by the coexistence of neuroendocrine and non-neuroendocrine components. These tumors exhibit distinct biological behavior and clinical significance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.